Top-Rated StocksTop-RatedNASDAQ:SLDB Solid Biosciences (SLDB) Stock Price, News & Analysis $2.74 +0.07 (+2.62%) Closing price 04/9/2025 04:00 PM EasternExtended Trading$2.74 0.00 (0.00%) As of 04/9/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Solid Biosciences Stock (NASDAQ:SLDB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Solid Biosciences alerts:Sign Up Key Stats Today's Range$2.47▼$2.8750-Day Range$2.67▼$6.4752-Week Range$2.48▼$11.28Volume1.65 million shsAverage Volume877,618 shsMarket Capitalization$212.33 millionP/E RatioN/ADividend YieldN/APrice Target$15.67Consensus RatingBuy Company OverviewSolid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Read More… Remove Ads Solid Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreSLDB MarketRank™: Solid Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 294th out of 904 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingSolid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSolid Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Solid Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Solid Biosciences are expected to grow in the coming year, from ($2.84) to ($2.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solid Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Solid Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSolid Biosciences has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Solid Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.51% of the float of Solid Biosciences has been sold short.Short Interest Ratio / Days to CoverSolid Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Solid Biosciences has recently increased by 7.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSolid Biosciences does not currently pay a dividend.Dividend GrowthSolid Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.51% of the float of Solid Biosciences has been sold short.Short Interest Ratio / Days to CoverSolid Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Solid Biosciences has recently increased by 7.10%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.21 News SentimentSolid Biosciences has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Solid Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 23 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat FollowsOnly 31 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Solid Biosciences insiders have sold 64.04% more of their company's stock than they have bought. Specifically, they have bought $9,932.00 in company stock and sold $16,292.00 in company stock.Percentage Held by Insiders13.63% of the stock of Solid Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Solid Biosciences' insider trading history. Receive SLDB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SLDB Stock News HeadlinesCan Solid Biosciences Challenge Sarepta in the DMD Market?Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.April 8 at 7:30 AM | marketbeat.comSolid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy SpaceApril 8 at 5:06 PM | seekingalpha.comThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.April 10, 2025 | Colonial Metals (Ad)Solid Biosciences reports inducement grants under Nasdaq listing ruleApril 2, 2025 | markets.businessinsider.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comTruist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB)March 21, 2025 | markets.businessinsider.comSolid Biosciences Inc. (SLDB): Among Top Insider Purchases Last MonthMarch 14, 2025 | insidermonkey.comSolid Biosciences (SLDB) Receives a Buy from J.P. MorganMarch 12, 2025 | markets.businessinsider.comSee More Headlines SLDB Stock Analysis - Frequently Asked Questions How have SLDB shares performed this year? Solid Biosciences' stock was trading at $4.00 at the beginning of the year. Since then, SLDB shares have decreased by 31.5% and is now trading at $2.74. View the best growth stocks for 2025 here. How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc. (NASDAQ:SLDB) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.12. When did Solid Biosciences' stock split? Solid Biosciences shares reverse split before market open on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Solid Biosciences IPO? Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. Who are Solid Biosciences' major shareholders? Solid Biosciences' top institutional shareholders include Rhumbline Advisers (0.05%). Insiders that own company stock include Perceptive Advisors Llc, Alexander Cumbo, Carl Ashley Morris, Jessie Hanrahan, Ilan Ganot, Gabriel Brooks, Paul Herzich and Clare Kahn. View institutional ownership trends. How do I buy shares of Solid Biosciences? Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings11/06/2024Today4/09/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLDB CIK1707502 Webwww.solidbio.com Phone(617) 337-4680FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$15.67 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+471.8%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.75% Return on Assets-47.84% Debt Debt-to-Equity RatioN/A Current Ratio7.85 Quick Ratio7.85 Sales & Book Value Annual Sales$8.09 million Price / Sales26.25 Cash FlowN/A Price / Cash FlowN/A Book Value$6.27 per share Price / Book0.44Miscellaneous Outstanding Shares77,493,000Free Float35,048,000Market Cap$212.33 million OptionableOptionable Beta2.07 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:SLDB) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersThe Most Bullish Metric For Stocks (NOT Volume…)Before placing a single trade, Tim Sykes always checks one key bullish metric. It’s the same signal that has s...MillPub | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWhy crypto may be the best way to play this chaotic market …Wall Street is in chaos … Over $6 trillion was wiped … in just two days. But something else was happenin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.